Intra-individual comparison of abbreviated gadoxetic acid–enhanced MRI and contrast-enhanced CT for postoperative surveillance of colorectal liver metastases: a multicenter prospective study
摘要
To intra-individually compare the diagnostic performance of hepatobiliary phase (HBP)-abbreviated MRI (AMRI) and contrast-enhanced CT (CE-CT) in postoperative surveillance of colorectal liver metastases (CRLMs).
MethodsThis multicenter prospective study enrolled 462 patients with colorectal cancer who underwent paired CE-CT and HBP-AMRI every six months over a 24-month surveillance period. The HBP-AMRI protocol comprised T2-weighted imaging, diffusion-weighted imaging, and HBP at 10 min post-injection, with total acquisition optimized to 5 min. Lesion detection rates for all and subcentimeter lesions, and patient-level sensitivity, specificity, and accuracy were compared between CE-CT and HBP-AMRI by McNemar χ2 test. Receiver operating characteristic (ROC) curves were constructed across all surveillance intervals.
ResultsHBP-AMRI demonstrated significantly higher detection rates than CE-CT across all surveillance rounds for all and subcentimeter lesions (all P < 0.05). The pooled 24-month data demonstrated HBP-AMRI significantly outperformed CE-CT in specificity (overall: 94.35% vs. 86.92%; P < 0.001), and accuracy (overall: 94.04% vs. 86.23%; P < 0.001). A consistent trend was observed across each individual surveillance round. The pooled 24-month analysis revealed HBP-AMRI had significantly higher sensitivity than CE-CT (overall: 90.35% vs. 78.07%; P = 0.023). HBP-AMRI maintained a superior negative predictive value (NPV) compared with CE-CT (overall: 99.14% vs. 97.91%), and higher positive predictive value (PPV) compared with CE-CT (overall: 57.54% vs. 33.59%) across all surveillance rounds.
ConclusionHBP-AMRI with a 5-minute streamlined workflow substantially outperforms CE-CT in lesion detection rate and patient-level diagnostic performance of CRLMs. HBP-AMRI can provide an efficient and safe alternative modality with longitudinal reliability for postoperative surveillance of CRLM in colorectal cancer patients.